Geraldine Henwood

This profile gathers the share dealings of Geraldine Henwood in Baudax Bio, Inc., where the filings describe the role as chief executive. Between 7 May 2021 and 15 December 2022, the trades on record add up to 6 filings.

The open-market record is one-sided, with 3 purchases worth €11k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 3 share grants. 2022 to date brings 1 purchase and no sales.

The median purchase comes to €4,105. Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 19 December 2022, reports an open-market purchase of €2,863 in Baudax Bio, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.